Biologic agents for rheumatoid arthritis: Can we hypothesize new strategies of treatment? Research in this field is obviously not encouraged by pharmaceutical industries, but the efforts should be driven in this direction. PubMed, Med Hypotheses, 09/02/2013. (Also see Rheumatoid Arthritis Treatments)
Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis (RA). One of the subjective components of the DAS28, patient VAS, was highly correlated with cognitive factors and depression in those with severe RA. Wiley Online Library, 12/13/2013. (Also see Rheumatoid Arthritis)
Patient-reported fatigue and its impact on patients with systemic lupus erythematosus. Understanding how patients with SLE describe the symptom of fatigue and how it impacts their lives is the key to better understanding how to measure fatigue in clinical studies evaluating new treatments for SLE. PubMed, Lupus, 11/06/2013. (Also see Systemic Lupus Erythematosus Symptoms)
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies (aPL). This meta-analysis shows that the risk of first thrombotic event is significantly decreased by low dose aspirin among asymptomatic aPL individuals, patients with systemic lupus erythematosus or obstetrical antiphospholipid syndrome. PubMed, Autoimmun Rev, 2013 Nov 2. pii: S1568-9972(13)00207-3. (Also see Antiphospholid Syndrome)
Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). A decreased mortality risk was seen with the prescription of antiplatelet therapy and the time period in which NPSLE was diagnosed did not significantly influence survival. PubMed, Lupus, 2013 Nov 15. (Also see Systemic Lupus Erythematosus Symptoms)
Autoantibodies and SLE-the threshold for disease. The current findings are summarized regarding the presence of SLE-associated antibodies in apparently healthy individuals, and provide opinions on what such discoveries might tell us about the roles of autoantibodies in the development of disease. PubMed, Nat Rev Rheumatol, 2013 Dec 3. (Also see Systemic Lupus Erythematosus Antibodies, and Autoantibodies)
Primary Sjögren's syndrome (pSS) - Fatigue is an ever-present, fluctuating and uncontrollable lack of energy. Fatigue in pSS clearly differs from ordinary tiredness. Patients describe it as ever-present, fluctuating and non-relievable lack of vitality being beyond own control. PubMed, Arthritis Care Res, 2013 Dec 10. (Also see Sjogren's Symptoms, and Fatigue)
Sleep Problems in Patients with Rheumatoid Arthritis (RA). Poor control of RA is associated with a reduction in sleep quality and decreased daytime sleepiness, which is likely explained by pain-related alertness. PubMed, J Rheumatol, 2013 Dec 1. (Also see Rheumatoid Arthritis, and Sleep Disorders and Illness)
Sleep as a biomarker for depression. Research on sleep in depression has provided several valuable biomarkers that are related to increased risk for depression, show worsening during depressive episode, and are related to treatment outcome and relapse risk during remission phase. PubMed, Int Rev Psychiatry, 2013 Oct;25(5):632-45. (Also see Sleep Disorders and Illness, and Depression)
Reading Voices of Scleroderma Books: Diana Kramer.
Sharing Scleroderma Awareness Bracelets: Deb Martin, Brenda Miller, Vickie Risner.
Thanks to UNITED WAY donors of Central New Mexico and Snohomish County!
Patricia Ann Black: Marilyn Currier, Shelley Ensz, Richard Howitt, Gerald and Pat Ivanejko, Juno Beach Condo Association, Keith and Rosalyn Miller, and Elaine Wible.
Gayle Hedlin: Daniel and Joann Pepper and Nancy Smithberg.
Janet Paulmenn: Anonymous, Mary Jo Austin, Shelley Blaser, Susan Book, Dennis and Pat Clayton, Grace Cunha, Cindy Dorio, Michael and Patricia Donahue, Shelley Ensz, Nancy Falkenhagen, Jo Frowde, Alice Gigl, Margaret Hollywood, Karen Khalaf and Family, Susan Kvarantan, Bradley Lawrence, Jillyan Little, Donna Madge, Michele Maxson, Barry and Judith McCabe, John Moffett, My Tribute Foundation, Joan-Marie Permison, John Roberts, Margaret Roof, Maryellen Ryan, Mayalin and Kiralee Murphy, Nancy Settle-Murphy, and Bruce and Elizabeth Winter.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content.